Equities research analysts expect that Horizon Pharma PLC (NASDAQ:HZNP) will announce earnings per share (EPS) of $0.50 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Horizon Pharma’s earnings, with estimates ranging from $0.47 to $0.53. Horizon Pharma posted earnings of $0.26 per share during the same quarter last year, which suggests a positive year over year growth rate of 92.3%. The firm is expected to announce its next earnings results before the market opens on Wednesday, November 7th.
According to Zacks, analysts expect that Horizon Pharma will report full year earnings of $1.58 per share for the current financial year, with EPS estimates ranging from $1.50 to $1.64. For the next financial year, analysts expect that the business will report earnings of $1.86 per share, with EPS estimates ranging from $1.60 to $2.12. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last released its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.17. Horizon Pharma had a positive return on equity of 19.05% and a negative net margin of 28.02%. The business had revenue of $302.84 million for the quarter, compared to analyst estimates of $275.51 million. During the same quarter last year, the firm posted $0.41 earnings per share. The business’s revenue was up 4.6% compared to the same quarter last year.
HZNP stock opened at $18.21 on Monday. The company has a debt-to-equity ratio of 2.19, a quick ratio of 1.63 and a current ratio of 1.70. Horizon Pharma has a twelve month low of $12.55 and a twelve month high of $21.25. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of 17.42, a price-to-earnings-growth ratio of 1.17 and a beta of 1.40.
In other news, EVP Geoffrey M. Curtis sold 9,904 shares of the firm’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $20.63, for a total transaction of $204,319.52. Following the transaction, the executive vice president now owns 28,767 shares in the company, valued at $593,463.21. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 3.90% of the company’s stock.
Several institutional investors have recently made changes to their positions in HZNP. Principal Financial Group Inc. increased its stake in shares of Horizon Pharma by 18.3% during the first quarter. Principal Financial Group Inc. now owns 555,534 shares of the biopharmaceutical company’s stock valued at $7,889,000 after buying an additional 85,970 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Horizon Pharma by 74.4% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 3,877 shares during the period. Millennium Management LLC increased its stake in shares of Horizon Pharma by 299.2% during the first quarter. Millennium Management LLC now owns 1,124,465 shares of the biopharmaceutical company’s stock valued at $15,967,000 after buying an additional 842,814 shares during the period. Brown Advisory Inc. increased its stake in shares of Horizon Pharma by 20.6% during the first quarter. Brown Advisory Inc. now owns 34,143 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 5,842 shares during the period. Finally, Bank of Montreal Can increased its stake in shares of Horizon Pharma by 6,596.4% during the second quarter. Bank of Montreal Can now owns 168,750 shares of the biopharmaceutical company’s stock valued at $2,794,000 after buying an additional 166,230 shares during the period. Hedge funds and other institutional investors own 86.87% of the company’s stock.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Featured Article: The Discount Rate – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.